In Vitro Activities of Ceftaroline and Comparators against Streptococcus pneumoniae Isolates from U.S. Hospitals: Results from Seven Years of the AWARE Surveillance Program (2010 to 2016)
Keyword(s):
ABSTRACT We evaluated trends in Streptococcus pneumoniae antimicrobial susceptibility in United States hospitals in the 2010 to 2016 period. A total of 8,768 clinical isolates from 47 medical centers were tested for susceptibility by broth microdilution methods. Multidrug-resistant (MDR) and extensively drug-resistant (XDR) rates decreased from 25.7% and 12.4%, respectively, in 2010 to 17.7% and 3.6%, respectively, in 2016. The susceptibilities to most comparator antimicrobial agents increased, whereas the susceptibilities to ceftaroline, levofloxacin, linezolid, and tigecycline remained stable. Ceftaroline retained potent activity against S. pneumoniae (>99.9%) with no marked variations.
2015 ◽
Vol 59
(6)
◽
pp. 3656-3659
◽
2015 ◽
Vol 03
(01)
◽
2015 ◽
Vol 59
(4)
◽
pp. 2458-2461
◽
2015 ◽
Vol 59
(6)
◽
pp. 3263-3270
◽
2013 ◽
Vol 57
(7)
◽
pp. 3178-3181
◽